11 Citazioni (Scopus)

Abstract

Abstract: Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tractcharacterized by recurring flares followed by periods of inactive disease and remission. Theetiology is unknown, although the common opinion is that the disease arises from a disorderedimmune response to the gut contents in genetically predisposed individuals. Infliximab (IFX),a chimeric immunoglobulin G1 monoclonal antibody to tumor necrosis factor, has dramaticallychanged the approach to managing patients with CD and improving their treatment, by achievingtreatment goals, such as mucosal healing, and decreasing the need for hospitalizations andsurgeries. This review provides an update on existing evidence for the use of IFX in CD, takinginto account the safety profile in clinical practice and special situations such as pregnancy.Antitumor necrosis factor therapy has been evaluated as an induction and maintenance therapyin CD in several randomized controlled trials and meta-analyses, showing efficacy in bothclinical settings. Early use of biologics may improve patient outcomes in active CD. However,a widespread use of a “top-down” approach in all CD patients cannot be recommended. Clinicalfactors at diagnosis may predict poor outcome in CD, and should be taken into account whendetermining the initial therapeutic approach.Keywords: Crohn’s disease, infliximab, adult
Lingua originaleEnglish
pagine (da-a)227-238
Numero di pagine12
RivistaClinical and Experimental Gastroenterology
Volume4
Stato di pubblicazionePublished - 2011

Fingerprint

Crohn Disease
Infliximab
Biological Products
Meta-Analysis
Immunoglobulins
Hospitalization
Chronic Disease
Necrosis
Therapeutics
Randomized Controlled Trials
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Maintenance
Safety
Pregnancy

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cita questo

Infliximab to treat Crohn's disease: an update. / Cottone, Mario.

In: Clinical and Experimental Gastroenterology, Vol. 4, 2011, pag. 227-238.

Risultato della ricerca: Article

@article{cc554495a4e547ae90f4a5531003d6c7,
title = "Infliximab to treat Crohn's disease: an update",
abstract = "Abstract: Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tractcharacterized by recurring flares followed by periods of inactive disease and remission. Theetiology is unknown, although the common opinion is that the disease arises from a disorderedimmune response to the gut contents in genetically predisposed individuals. Infliximab (IFX),a chimeric immunoglobulin G1 monoclonal antibody to tumor necrosis factor, has dramaticallychanged the approach to managing patients with CD and improving their treatment, by achievingtreatment goals, such as mucosal healing, and decreasing the need for hospitalizations andsurgeries. This review provides an update on existing evidence for the use of IFX in CD, takinginto account the safety profile in clinical practice and special situations such as pregnancy.Antitumor necrosis factor therapy has been evaluated as an induction and maintenance therapyin CD in several randomized controlled trials and meta-analyses, showing efficacy in bothclinical settings. Early use of biologics may improve patient outcomes in active CD. However,a widespread use of a “top-down” approach in all CD patients cannot be recommended. Clinicalfactors at diagnosis may predict poor outcome in CD, and should be taken into account whendetermining the initial therapeutic approach.Keywords: Crohn’s disease, infliximab, adult",
author = "Mario Cottone",
year = "2011",
language = "English",
volume = "4",
pages = "227--238",
journal = "Clinical and Experimental Gastroenterology",
issn = "1178-7023",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Infliximab to treat Crohn's disease: an update

AU - Cottone, Mario

PY - 2011

Y1 - 2011

N2 - Abstract: Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tractcharacterized by recurring flares followed by periods of inactive disease and remission. Theetiology is unknown, although the common opinion is that the disease arises from a disorderedimmune response to the gut contents in genetically predisposed individuals. Infliximab (IFX),a chimeric immunoglobulin G1 monoclonal antibody to tumor necrosis factor, has dramaticallychanged the approach to managing patients with CD and improving their treatment, by achievingtreatment goals, such as mucosal healing, and decreasing the need for hospitalizations andsurgeries. This review provides an update on existing evidence for the use of IFX in CD, takinginto account the safety profile in clinical practice and special situations such as pregnancy.Antitumor necrosis factor therapy has been evaluated as an induction and maintenance therapyin CD in several randomized controlled trials and meta-analyses, showing efficacy in bothclinical settings. Early use of biologics may improve patient outcomes in active CD. However,a widespread use of a “top-down” approach in all CD patients cannot be recommended. Clinicalfactors at diagnosis may predict poor outcome in CD, and should be taken into account whendetermining the initial therapeutic approach.Keywords: Crohn’s disease, infliximab, adult

AB - Abstract: Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tractcharacterized by recurring flares followed by periods of inactive disease and remission. Theetiology is unknown, although the common opinion is that the disease arises from a disorderedimmune response to the gut contents in genetically predisposed individuals. Infliximab (IFX),a chimeric immunoglobulin G1 monoclonal antibody to tumor necrosis factor, has dramaticallychanged the approach to managing patients with CD and improving their treatment, by achievingtreatment goals, such as mucosal healing, and decreasing the need for hospitalizations andsurgeries. This review provides an update on existing evidence for the use of IFX in CD, takinginto account the safety profile in clinical practice and special situations such as pregnancy.Antitumor necrosis factor therapy has been evaluated as an induction and maintenance therapyin CD in several randomized controlled trials and meta-analyses, showing efficacy in bothclinical settings. Early use of biologics may improve patient outcomes in active CD. However,a widespread use of a “top-down” approach in all CD patients cannot be recommended. Clinicalfactors at diagnosis may predict poor outcome in CD, and should be taken into account whendetermining the initial therapeutic approach.Keywords: Crohn’s disease, infliximab, adult

UR - http://hdl.handle.net/10447/64616

M3 - Article

VL - 4

SP - 227

EP - 238

JO - Clinical and Experimental Gastroenterology

JF - Clinical and Experimental Gastroenterology

SN - 1178-7023

ER -